Startup Mosanna Therapeutics announced that it has closed a $80 million Series A financing that will fund Phase 2 development of the company’s MOS118 nasal spray for the treatment of obstructive sleep apnea. Mosanna also announced the appointment of David Weber as its new President and CEO. Weber was most recently President and CEO of Otonomy.
In 2022, CDMO MedPharm announced that it would provide formulation and delivery development services for MOS118, a potassium channel blocker that was initially developed by Sanofi. According to Mosanna’s announcement, the nasal spray is currently in a Phase 1 trial.
Weber commented, “Mosanna is taking a truly transformational approach to sleep apnea treatment, offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life. No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep, delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.”
Read the Mosanna Therapeutics press release
